Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • ARCA Cy5 EGFP mRNA (5-moUTP): Fluorescently Labeled mRNA ...

    2025-11-17

    ARCA Cy5 EGFP mRNA (5-moUTP): Fluorescently Labeled mRNA for High-Precision Delivery and Translation Analysis

    Executive Summary: ARCA Cy5 EGFP mRNA (5-moUTP) is a 996-nt, 5-methoxyuridine (5-moUTP) modified mRNA encoding enhanced green fluorescent protein (EGFP), labeled with Cyanine 5 (Cy5) for direct visualization independent of translation. This reagent is capped with a Cap 0 structure and polyadenylated, mimicking mature mammalian mRNA to optimize expression and stability in cell culture (APExBIO). The 1:3 Cy5-UTP:5-moUTP ratio balances visualization and translation efficiency. Modified nucleotides suppress innate immune activation, supporting sensitive localization and translation assays (Huang et al. 2022). This product is widely used as a benchmark control in mRNA delivery system research and quantitative workflow optimization (see guide).

    Biological Rationale

    Messenger RNA (mRNA) is a transient, non-integrating template for protein synthesis in eukaryotic cells. Modified mRNA enables programmable gene expression, avoiding risks of genomic integration associated with DNA-based approaches (Huang et al. 2022). The use of 5-methoxyuridine (5-moUTP) reduces recognition by innate immune sensors, improving translation and cell viability (Precision Tools for Quantitative Analysis). Fluorescent labeling of mRNA with dyes such as Cy5 allows direct monitoring of delivery and intracellular localization, independent of translation outcomes. This dual-modality approach is essential for dissecting the efficiency of delivery vehicles and tracking mRNA fate in real time. The EGFP coding sequence, derived from Aequorea victoria, provides a secondary readout of translation efficacy, enabling precise decoupling of delivery from protein expression events.

    Mechanism of Action of ARCA Cy5 EGFP mRNA (5-moUTP)

    ARCA Cy5 EGFP mRNA (5-moUTP) is synthesized by in vitro transcription, incorporating a 1:3 molar ratio of Cy5-UTP to 5-moUTP. The Cy5 dye (λex: 650 nm, λem: 670 nm) enables direct fluorescence detection of intact mRNA molecules via microscopy or flow cytometry. The 5-moUTP modification reduces mRNA’s immunogenicity by limiting Toll-like receptor activation. A co-transcriptionally added cap analog (Anti-Reverse Cap Analog, ARCA) generates a Cap 0 structure, enhancing ribosome recruitment and translation initiation. A poly(A) tail increases mRNA stability and mimics native eukaryotic transcripts. Upon transfection, the labeled mRNA is internalized by mammalian cells—often using lipid nanoparticles or cationic polymers—where it can be visualized (Cy5 channel) and translated into EGFP (λem: 509 nm) for functional readout. Direct Cy5 detection confirms cytosolic delivery even in the absence of translation, distinguishing effective uptake from functional expression.

    Evidence & Benchmarks

    • 5-methoxyuridine incorporation in mRNA suppresses activation of innate immune sensors, enabling higher translation efficiency in mammalian cells (Huang et al. 2022, https://doi.org/10.1002/advs.202205532).
    • Lipid nanoparticle (LNP) delivery of modified mRNAs achieves robust cytoplasmic localization and protein expression in vivo, with high efficiency and reduced degradation (Huang et al. 2022).
    • Fluorescently labeled mRNA (e.g., Cy5) permits direct visualization of delivery events and enables quantitative assessment of intracellular localization, independent of translation (https://cy5-utp.com/index.php?g=Wap&m=Article&a=detail&id=10882).
    • The Cap 0 structure generated by co-transcriptional capping enhances translation initiation by improving eukaryotic ribosome binding (2xpowderblend.com).
    • ARCA Cy5 EGFP mRNA (5-moUTP) at 1 mg/mL in 1 mM sodium citrate (pH 6.4) remains stable at -40°C or below, with minimal degradation over multiple months (APExBIO, product page).
    • Direct multiplexed analysis of mRNA uptake (Cy5 fluorescence) and translation (EGFP fluorescence) enables workflow optimization and troubleshooting in real time (cy5-utp.com).

    For a detailed comparison with previous approaches, see "ARCA Cy5 EGFP mRNA (5-moUTP): Optimizing Fluorescent mRNA Delivery Workflows", which this article extends by providing updated practical benchmarks and immune suppression data.

    Applications, Limits & Misconceptions

    ARCA Cy5 EGFP mRNA (5-moUTP) is optimized for experimental quantification of mRNA delivery, localization, and translation in mammalian cell culture. It is commonly used as a positive control or reference in transfection optimization, delivery vehicle benchmarking, and immune evasion studies. The dual readout (Cy5 for mRNA, EGFP for translation) supports high-content imaging and flow cytometry analyses. This reagent is not intended for use in live animals, clinical applications, or gene editing workflows. The Cy5 label is stable under recommended storage and handling conditions but may be sensitive to photobleaching under intense illumination. The product’s 1:3 Cy5-UTP:5-moUTP ratio is optimized for balance; higher dye incorporation can impair translation. For further troubleshooting guidance, see "Optimizing mRNA Delivery and Analysis with ARCA Cy5 EGFP mRNA (5-moUTP)", which this article clarifies by detailing platform-specific pitfalls.

    Common Pitfalls or Misconceptions

    • Not for in vivo/clinical use: The product is for research use only; it is not designed for animal studies or therapeutic applications.
    • Translation dependence: Cy5 fluorescence reports mRNA presence, not translation; lack of EGFP signal may reflect delivery or translation block.
    • Photobleaching: Cy5 is sensitive to prolonged high-intensity illumination; minimize light exposure during imaging.
    • RNase contamination: Product is highly sensitive to RNases; strict RNase-free technique is essential.
    • Improper buffer or storage: Use only the supplied buffer (1 mM sodium citrate, pH 6.4), and store at -40°C or below to prevent degradation.

    Workflow Integration & Parameters

    For optimal performance, ARCA Cy5 EGFP mRNA (5-moUTP) should be thawed on ice and handled with RNase-free consumables. Do not vortex; mix gently. Combine mRNA with a validated transfection reagent before adding to serum-containing media. Typical working concentrations are 0.1–2 μg/mL, depending on cell line and assay sensitivity. Cy5 fluorescence can be detected by excitation at 650 nm and emission at 670 nm; EGFP is monitored at 488 nm excitation/509 nm emission. Avoid repeated freeze-thaw cycles. For detailed quantitative workflow protocols, see "ARCA Cy5 EGFP mRNA (5-moUTP): Advanced Tools for Quantitative mRNA Delivery System Research", which this article updates with recent immunogenicity findings.

    Conclusion & Outlook

    ARCA Cy5 EGFP mRNA (5-moUTP) from APExBIO provides a rigorously validated, dual-modality tool for dissecting mRNA delivery and translation efficiency in mammalian cells. Its robust chemical modifications balance innate immune suppression, high translation efficiency, and quantitative fluorescence readouts. As mRNA-based technologies expand in research and therapeutic settings, such reagents will remain central to workflow optimization and benchmarking. Ongoing innovations in delivery systems and mRNA engineering will further enhance the utility of fluorescently labeled, immune-silent mRNA reporters.

    For the full product specification, ordering, and validated protocols, visit the ARCA Cy5 EGFP mRNA (5-moUTP) product page.